COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Hemab Therapeutics Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$32.09+2.02 (+6.72%)
Close on Oct 19, 2026
- Market cap
- $966.27M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Hemab Therapeutics has not reported a dividend
No dividend per share appears in Hemab Therapeutics's annual filings since fiscal 2025.